T1	Participants 97 125	adults with type 1 diabetes.
T2	Participants 209 257	intensively treated adults with type 1 diabetes.
T3	Participants 297 459	83 of 86 individuals >or=25 years of age with type 1 diabetes who used CGM as part of a 6-month randomized clinical trial in a subsequent 6-month extension study.
T4	Participants 980 1027	intensively treated adults with type 1 diabetes
